|
1
|
Yan Y, Zhao J, Cao C, Jia Z, Zhou N, Han
S, Wang Y, Xu Y, Zhao J, Yan Y, et al: Tetramethylpyrazine promotes
SH-SY5Y cell differentiation into neurons through epigenetic
regulation of Topoisomerase IIβ. Neuroscience. 278:179–193. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang L, Zhang X, Cui G, Chan JY, Wang L,
Li C, Shan L, Xu C, Zhang Q, Wang Y, et al: A novel agent exerts
antitumor activity in breast cancer cells by targeting
mitochondrial complex II. Oncotarget. Mar 27–2016.(Epub ahead of
print).
|
|
3
|
Kao TK, Chang CY, Ou YC, Chen WY, Kuan YH,
Pan HC, Liao SL, Li GZ and Chen CJ: Tetramethylpyrazine reduces
cellular inflammatory response following permanent focal cerebral
ischemia in rats. Exp Neurol. 247:188–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu X, Liu H, Zeng Z, Zhou W, Liu J and He
Z: Pharmacokinetics of ligustrazine ethosome patch in rats and
anti-myocardial ischemia and anti-ischemic reperfusion injury
effect. Int J Nanomed. 6:1391–1398. 2011. View Article : Google Scholar
|
|
5
|
Jia Y, Wang Z, Zang A, Jiao S, Chen S and
Fu Y: Tetramethylpyrazine inhibits tumor growth of lung cancer
through disrupting angiogenesis via BMP/Smad/Id-1 signaling. Int J
Oncol. 48:2079–2086. 2016.PubMed/NCBI
|
|
6
|
Kim M, Kim SO, Lee M, Lee JH, Jung WS,
Moon SK, Kim YS, Cho KH, Ko CN and Lee EH: Tetramethylpyrazine, a
natural alkaloid, attenuates pro-inflammatory mediators induced by
amyloid β and interferon-γ in rat brain microglia. Eur J Pharmacol.
740:504–511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang XJ, Xu YH, Yang GC, Chen HX and Zhang
P: Tetramethylpyrazine inhibits the proliferation of acute
lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep.
33:2368–2374. 2015.PubMed/NCBI
|
|
8
|
Zhang P, Zheng BB, Wang HY, Chen JH, Liu
XY and Guo XL: DLJ14, a novel chemo-sensitization agent, enhances
therapeutic effects of adriamycin against MCF-7/A cells both in
vitro and in vivo. J Pharm Pharmacol. 66:398–407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yi B, Liu D, He M, Li Q, Liu T and Shao J:
Role of the ROS/AMPK signaling pathway in
tetramethylpyrazine-induced apoptosis in gastric cancer cells.
Oncol Lett. 6:583–589. 2013.PubMed/NCBI
|
|
10
|
Chen Z, Pan X, Georgakilas AG, Chen P, Hu
H, Yang Y, Tian S, Xia L, Zhang J, Cai X, et al:
Tetramethylpyrazine (TMP) protects cerebral neurocytes and inhibits
glioma by down regulating chemokine receptor CXCR4 expression.
Cancer Lett. 336:281–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
|
12
|
Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li
X, Zhao C, Zhang L, Cai W and Zhou C: Long non-coding RNA BC087858
induces non-T790M mutation acquired resistance to EGFR-TKIs by
activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell
lung cancer. Oncotarget. Jul 9–2016.(Epub ahead of print).
|
|
13
|
Bonyadi Rad E, Hammerlindl H, Wels C,
Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner
C, Herlyn M, Bergler H, et al: Notch4 signaling induces a
mesenchymal-epithelial-like transition in melanoma cells to
suppress malignant behaviors. Cancer Res. 76:1690–1697. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raza U, Saatci Ö, Uhlmann S, Ansari SA,
Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK and Zhang J:
The miR-644a/CTBP1/p53 axis suppresses drug resistance by
simultaneous inhibition of cell survival and epithelial-mesenchymal
transition in breast cancer. Oncotarget. Jul 8–2016.(Epub ahead of
print). PubMed/NCBI
|
|
15
|
Matusali G, Tchidjou HK, Pontrelli G,
Bernardi S, D’ Ettorre G, Vullo V, Buonomini AR, Andreoni M,
Santoni A, Cerboni C and Doria M: Soluble ligands for the NKG2D
receptor are released during HIV-1 infection and impair NKG2D
expression and cytotoxicity of NK cells. FASEB J. 27:2440–2450.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guerra N, Tan YX, Joncker NT, Choy A,
Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM and Raulet
DH: NKG2D-deficient mice are defective in tumor surveillance in
models of spontaneous malignancy. Immunity. 28:571–580. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
López-Larrea C, Suárez-Alvarez B,
López-Soto A, López-Vázquez A and Gonzalez S: The NKG2D receptor:
Sensing stressed cells. Trends Mol Med. 14:179–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cosman D, Müllberg J, Sutherland CL, Chin
W, Armitage R, Fanslow W, Kubin M and Chalupny NJ: ULBPs, novel MHC
class I-related molecules, bind to CMV glycoprotein UL16 and
stimulate NK cytotoxicity through the NKG2D receptor. Immunity.
14:123–133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
López-Soto A, Zapico LH, Acebes-Huerta A,
Rodrigo L and Gonzalez S: Regulation of NKG2D signaling during the
epithelial-to-mesenchymal transition. Oncoimmunology. 2:e258202013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y,
Ai Q, Zhang P, Song EL, Huang QB, et al: Downregulation of FOXO3a
promotes tumor metastasis and is associated with metastasis-free
survival of patients with clear cell renal cell carcinoma. Clin
Cancer Res. 20:1779–1790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia HY, Liu JL, Yuan MZ, Zhou CJ, Sun WD,
Zhao JJ, Wang J, Liu L and Luan Y: Regulation roles of MICA and
NKG2D in human renal cancer cells. Asian Pac J Cancer Prev.
16:3901–3905. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Subramani R, Gonzalez E, Nandy SB,
Arumugam A, Camacho F, Medel J, Alabi D and Lakshmanaswamy R:
Gedunin inhibits pancreatic cancer by altering sonic hedgehog
signaling pathway. Oncotarget. Mar 14–2016. View Article : Google Scholar : (Epub ahead of
print). PubMed/NCBI
|
|
23
|
Friese MA, Wischhusen J, Wick W, Weiler M,
Eisele G, Steinle A and Weller M: RNA interference targeting
transforming growth factor-beta enhances NKG2D-mediated antiglioma
immune response, inhibits glioma cell migration and invasiveness,
and abrogates tumorigenicity in vivo. Cancer Res. 64:7596–7603.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang F, Shao Y, Yang F, Liu M, Huang J,
Zhu K, Guo C, Luo J, Li W, Yang B, et al: Valproic acid upregulates
NKG2D ligand expression and enhances susceptibility of human renal
carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci.
9:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mikami S, Mizuno R, Kosaka T, Saya H, Oya
M and Okada Y: Expression of TNF-α and CD44 is implicated in poor
prognosis, cancer cell invasion, metastasis and resistance to the
sunitinib treatment in clear cell renal cell carcinomas. Int J
Cancer. 136:1504–1514. 2015. View Article : Google Scholar
|
|
26
|
Hill B, De Melo J, Yan J, Kapoor A, He L,
Cutz JC, Feng X, Bakhtyar N and Tang D: Common reduction of the Raf
kinase inhibitory protein in clear cell renal cell carcinoma.
Oncotarget. 5:7406–7419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lawrie CH, Larrea E, Larrinaga G,
Goicoechea I, Arestin M, Fernandez-Mercado M, Hes O, Cáceres F,
Manterola L and López JI: Targeted next-generation sequencing and
non-coding RNA expression analysis of clear cell papillary renal
cell carcinoma suggests distinct pathological mechanisms from other
renal tumour subtypes. J Pathol. 232:32–42. 2014. View Article : Google Scholar
|
|
28
|
Zhang X, Yan L, Jiao W, Ren J, Xing N,
Zhang Y, Zang Y, Wang J and Xu Z: The clinical and biological
significance of MICA in clear cell renal cell carcinoma patients.
Tumour Biol. 37:2153–2159. 2016. View Article : Google Scholar
|
|
29
|
López-Soto A, Huergo-Zapico L, Galván JA,
Rodrigo L, de Herreros AG, Astudillo A and Gonzalez S:
Epithelial-mesenchymal transition induces an antitumor immune
response mediated by NKG2D receptor. J Immunol. 190:4408–4419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eisele G, Wischhusen J, Mittelbronn M,
Meyermann R, Waldhauer I, Steinle A, Weller M and Friese MA: TGF-β
and metalloproteinases differentially suppress NKG2D ligand surface
expression on malignant glioma cells. Brain. 129:2416–2425. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kunigal S, Lakka SS, Joseph P, Estes N and
Rao JS: Matrix metalloproteinase-9 inhibition down-regulates
radiation-induced nuclear factor-kappa B activity leading to
apoptosis in breast tumors. Clin Cancer Res. 14:3617–3626. 2008.
View Article : Google Scholar : PubMed/NCBI
|
